Published in final edited form as:

Transplantation. 2013 March 27; 95(6): 787–790. doi:10.1097/TP.0b013e318282f282.

Willingness to Pursue Live Donor Kidney Transplantation Among Wait-Listed Patients Infected with Human Immunodeficiency Virus (HIV): A Preliminary Investigation

James R. Rodrigue, PhD¹, Matthew J. Paek, MA¹, Ogo Egbuna, MD², Amy D. Waterman, PhD³, Martha Pavlakis, MD¹, and Didier A. Mandelbrot, MD¹

James R. Rodrigue: jrrodrig@bidmc.harvard.edu; Matthew J. Paek: matthewjared07@gmail.com; Ogo Egbuna: ogoegbuna@gmail.com; Amy D. Waterman: awaterma@dom.wustl.edu; Martha Pavlakis: mpavlaki@bidmc.harvard.edu; Didier A. Mandelbrot: mandelb@bidmc.harvard.edu

¹Center for Transplant Outcomes and Quality Improvement, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA and the Harvard Medical School, Boston, MA, USA

²Amgen, Inc., Thousand Oaks, CA, USA

³Washington University School of Medicine, St. Louis, MO, USA

Abstract

We show that HIV-infected wait-listed patients ($n = 33$) had significantly lower knowledge ($P < 0.001$), more concerns ($P = 0.01$), and lower willingness to pursue LDKT ($P = 0.02$) than matched non-infected patients. The majority (78%) of patients felt that their HIV status reduced their chance of LDKT. While limited to a single center and a small sample, our data suggest that HIV-infected patients who are wait-listed for kidney transplantation may need more education about the potential benefits of LDKT and may benefit from patient-center decision support to facilitate a risk-benefit assessment consistent with their preferences and values.

Keywords

kidney transplantation; living donation; live donor kidney transplant; human immunodeficiency virus

INTRODUCTION

For those infected with human immunodeficiency virus (HIV), longer survival has been accompanied by a higher rate of kidney disease (1,2). During the pre-HAART era, HIV-infected patients with renal failure were not considered kidney transplant candidates due to concerns about more rapid progression to acquired immune deficiency syndrome (AIDS) and poor outcomes (3,4). While there is evidence of higher rates of acute rejection (5), graft

Corresponding author: James R. Rodrigue, Ph.D., The Transplant Institute, Beth Israel Deaconess Medical Center, 110 Francis Street, 7th Floor, Boston, MA 02215, (617) 632-9821 (phone), (617) 632-9820 (fax), jrrodrig@bidmc.harvard.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

There are no conflicts of interest to report. Dr. Egbuna was a faculty member and transplant nephrologist at Beth Israel Deaconess Medical Center and Harvard Medical School during the development and initial implementation of the study. He is now employed as Clinical Research Medical Director for Amgen Inc., although Amgen has not been involved in any way with the study reported in this manuscript.

and patient survival outcomes following kidney transplantation for carefully selected patients who are HIV-infected are similar to those of non-infected patients (6–8).

While live donor kidney transplantation (LDKT) yields superior outcomes relative to deceased donor transplantation (9), HIV-infected patients may encounter unique LDKT barriers. For instance, some patients and their non-transplant providers may not recognize the favorable transplant outcomes for those with HIV and may not feel it is appropriate to ask others to consider living donation. Some transplant programs may require disclosure of HIV to potential living donors, which cause reluctance in some patients because of social stigma concerns. Therefore, we examined the LDKT willingness, readiness, knowledge and concerns of wait-listed HIV-infected patients in comparison to non-infected patients.

RESULTS

Thirty-three HIV-infected patients completed study questionnaires (85% participation rate). HIV-infected and non-infected ($n = 33$) patients did not differ significantly on matched (age: 47.2 yrs vs. 47.4 yrs, $P = 0.96$; female gender: 30% vs. 30%, $P = 1.00$; non-white race: 48% vs. 48%, $P = 1.00$; waiting time: 13.7 months vs. 12.8 months, $P = 0.82$) and non-matched (college education: 27% vs. 18%, $P = 0.38$; married: 39% vs. 45%, $P = 0.62$; employed: 24% vs. 27%, $P = 0.78$; dialysis: 85% vs. 76%, $P = 0.35$; dialysis duration: 43.0 vs. 32.9, $P = 0.44$) variables. None of the primary outcomes varied significantly by gender, age, education, marital status, employment, waiting list time, or dialysis status (P values > 0.05). Non-white patients had lower LDKT knowledge ($P = 0.02$) and lower willingness to pursue LDKT ($P = 0.03$) than white patients, although the HIV status by race interaction effect was not statistically significant.

Compared to non-infected patients, HIV-infected patients reported lower willingness to talk to family members and/or friends about living donation ($P = 0.02$), less LDKT knowledge ($P < 0.001$), and more LDKT concerns ($P = 0.01$) (Table 1). HIV-infected patients were less likely than non-infected patients to know that a person with hypertension could potentially be a living donor at our center (24% vs. 48%, $P = 0.04$), most donors can return to work in less than 6 weeks (55% vs. 78%, $P = 0.04$), kidney donation does not typically increase the risk of future renal failure (39% vs. 64%, $P = 0.05$), and incompatible donors can still benefit the intended recipient through kidney or list exchange (27% vs. 58%, $P = 0.01$).

HIV-infected patients reported more concern that nobody would volunteer to be a living donor (3.3 vs. 2.6, $P = 0.04$), transplant providers would pressure someone to be a donor (1.7 vs. 1.2, $P = 0.05$), transplant providers would be angry if no family members agree to be a donor (1.6 vs. 1.1, $P = 0.04$), they would feel guilty if testing showed someone to be a donor match (3.0 vs. 1.4, $P = 0.01$), and they might do something to “waste” the donated kidney (2.0 vs. 1.4, $P = 0.03$). Non-infected patients were more concerned that they would die if a living donor was not found (2.9 vs. 2.1, $P = 0.05$).

Readiness to pursue LDKT differed significantly by HIV status ($\chi^2 = 10.1$, $P = 0.04$). Relative to non-infected patients, more HIV-infected patients were not considering LDKT (42% vs. 21%) and fewer were in “action” stages of readiness (6% vs. 12%), i.e., had already talked to someone who was considering living donation or who had already contacted the transplant program (Figure 1).

On average, HIV-infected patients identified 2.6 (± 2.8) primary sources of LDKT information compared to 4.1 (± 2.7) for non-infected patients ($t = 2.3$, $P = 0.024$). HIV-infected patients were less likely than non-infected patients to identify another transplant patient as a primary source of LDKT information (21% vs. 48%, $P = 0.04$), and there were trends ($P < 0.10$) showing that HIV-infected patients were less likely to identify healthcare

providers (64% vs. 85%), family members (30% vs. 55%), and friends (24% vs. 48%) as sources of LDKT information.

Most infected patients considered their HIV status to be a barrier to discussing living donation (82%) and felt uncomfortable sharing their HIV status with others (73%). (Table 2) Only one-third (36%) would share their HIV status with others if it would facilitate getting a LDKT. Willingness to share HIV status with potential donors was not significantly associated with sociodemographic characteristics, medical characteristics, or quality of life scores ($P > 0.05$).

DISCUSSION

We found that HIV-infected patients have less knowledge about LDKT, have more concerns about LDKT, and are less willing to pursue LDKT than those without HIV. Moreover, most perceive their HIV status to be a barrier to LDKT. Social stigma persists for those who are HIV-infected (10,11) and concerns about disclosing one's HIV status may partially explain the lower LDKT rate in this population. Although some patients are willing to disclose HIV status with potential donors if it helps facilitate LDKT, most patients in our study felt uncomfortable doing so and felt that being infected represented a barrier to LDKT.

Such perceived barriers also may account for the finding that fewer HIV-infected patients were seriously considering this transplant option or had talked to someone about donation. While the same number of both HIV-infected and non-infected patients had a potential donor who already had contacted the transplant program, fewer HIV-infected patients were in other "action" stages of thinking about or pursuing LDKT. This may lead to fewer potential donors being evaluated or longer time before a potential donor initiates an evaluation. Less knowledge and more concerns about LDKT may further affect willingness to pursue this transplant option among HIV-infected patients, although these differences were unexpected because our educational processes do not vary by HIV status. Indeed, HIV-infected patients had less overall exposure to LDKT information, which likely reflects their pre-contemplation stage of LDKT readiness and/or perceived barriers attributed to their HIV status.

There is some debate about whether a recipient's HIV-infection status should be disclosed to potential living donors (12,13). Consensus guidelines, however, are nonspecific on this issue, stating only that potential donors be informed of factors that increase risk of recipient morbidity or mortality. Recently, we reported that most potential donors would not alter their donation decision if they learned that the intended recipient was HIV-infected (14). However, 58% of these same adults and 71% of former donors felt that the HIV status of intended recipients should be disclosed to potential donors. Our program does not require recipients to disclose their HIV status to potential donors. We believe that potential donors should be informed of medical, surgical, and psychosocial factors that heighten the recipient's morbidity and mortality risk, and we work collaboratively with potential donors and recipients under these circumstances to ensure an informed risk-benefit assessment.

Whether or not a transplant program requires HIV disclosure to potential donors, there may be a need to tailor LDKT education to address the unique circumstances of this subgroup of patients. We did not assess this directly in the study, but anecdotally it was our observation that some patients were not aware of current transplant outcomes for HIV-infected patients and, therefore, may not have been as proactive as non-infected patients in seeking more information about the benefits LDKT. It is also possible that non-transplant providers are similarly unaware of the potential benefits of kidney transplantation in patients with HIV and do not educate their patients about LDKT. Moreover, some may not know that our

program does not require the disclosure of their HIV status to potential living donors, which may contribute to their lower willingness to pursue this particular treatment option. HIV-infected patients may need assistance in making an assessment of both the benefits (e.g., reduced dialysis exposure, transplant outcomes for HIV-infected patients) and risks (e.g., social stigma if others learn of HIV status) of LDKT so they can make a treatment decision that is consistent with their preferences and values.

In conclusion, data from several studies show that carefully selected HIV-infected patients with renal failure benefit from transplantation. The current study shows, however, that HIV-infected patients have many concerns about pursuing LDKT and are less willing or ready to consider this treatment option compared to a matched group of non-infected patients. A patient-centered decision support approach that considers the unique circumstances of HIV-infected patients may be beneficial for this patient population. Importantly, this was a single-center study and it is limited by its small sample size, which did not permit us to conduct multivariate analyses to isolate the independent effects of HIV status on the study outcomes. Also, we developed a questionnaire to assess the specific HIV-related concerns of patients and this instrument has not been validated. More research with a larger cohort of HIV-infected patients is needed to better understand the lower LDKT willingness in this unique population and barriers that may adversely affect access to this superior treatment option.

METHODS

HIV-infected patients approved for kidney transplantation were matched sequentially 1:1 with non-infected patients on year of evaluation, age (± 5 yrs), sex, race (white, non-white), and waiting time (± 1 yr). All patients were participating in a larger study on strategies to increase LDKT rates, but had not been randomized to receive the assigned intervention at the time of the questionnaire assessment described herein. Patients were excluded if they were awaiting combined kidney-liver transplantation or did not speak/comprehend English or Spanish.

All patients were identified in our electronic transplant database and then approached privately by our study coordinator during a transplant clinic appointment. The coordinator was not involved in the clinical care of patients. Patients were informed of the study procedures, time commitment, and that none of their individual responses would be shared with their transplant providers. Written informed consent was then obtained and study questionnaires were completed. Patients were compensated \$20. Research procedures were approved by the institutional review board.

At our center, HIV-infected patients must meet standard medical, surgical, and psychosocial criteria for placement on the transplant waiting list, be on a stable antiretroviral regimen for at least three months prior to listing or be able to maintain a persistently undetectable HIV-1 RNA level, have a CD4 T-cell count $\geq 200/\text{mL}$ for the past six months, and have or be willing to start seeing a primary medical care provider with expertise in HIV management. Also, patients with opportunistic complications are considered on a case-by-case basis if they have received appropriate acute and maintenance therapy and have no evidence of active disease. However, patients are not eligible for transplantation if they have a history of diseases caused by aspergillus or aspergillus colonization, a history of documented resistant fungal infections, or a history of neoplasm (excl. cutaneous Kaposi's sarcoma, *in situ* anogenital carcinoma, adequately treated basal- or squamous-cell carcinoma of the skin, or solid tumors treated with curative therapy and disease-free for more than five years). Our center participated in the multi-site observational cohort study on kidney and liver transplantation in HIV-infected adults (8); however, we did not recruit patients who were participating in the multi-site cohort study.

Patients completed several validated questionnaires that have been used in prior studies (Table 3) (15–18). Additionally, we gathered the following information from the patient's medical record: age, sex, race/ethnicity, education, marital status, primary renal disease etiology, dialysis status and duration, year of evaluation and listing, and months on the waiting list.

Descriptive statistics were calculated to summarize the sociodemographic and medical characteristics of patients, as well as the questionnaire responses. Differences between HIV-infected and non-infected patients were examined using t tests for continuous variables and Fisher's exact test (χ^2) or chi square test for categorical variables. Findings of $P < 0.05$ were considered statistically significant. PASW 17.0 (Chicago, IL) was used for all statistical analyses.

Acknowledgments

We are thankful for the data collection and entry assistance we received from Timothy Antonellis, Jonathan Berkman, Ariel Hodara, Richard McCartney, Colleen Morse, Stacey Senat, and Hongying Tang.

The project described is supported by Award Number R01DK079665 from the National Institute of Diabetes and Digestive and Kidney Diseases (JRR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes and Digestive and Kidney Diseases or the National Institutes of Health. This research was also supported, in part, by the Julie Henry Research Fund and the Center for Transplant Outcomes and Quality Improvement, The Transplant Institute, Beth Israel Deaconess Medical Center, Boston, MA.

Abbreviations

AIDS	acquired immune deficiency syndrome
CI	Confidence interval
ESRD	End-stage renal disease
HAART	highly active anti-retroviral therapy
HIV	Human immunodeficiency virus
LDKT	Live donor kidney transplantation
OR	Odds ratio

REFERENCES

1. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. *Clin Infect Dis*. 2011; 53:1120–1126. [PubMed: 21998278]
2. Wyatt CM, Klotman PE. HIV-associated nephropathy in the era of antiretroviral therapy. *Am J Med*. 2007; 120:488–492. [PubMed: 17524746]
3. Rubin RH, Jenkins RL, Shaw BW, et al. The acquired immunodeficiency syndrome and transplantation. *Transplantation*. 1987; 44:1–4. [PubMed: 3299908]
4. Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. *Transplantation*. 1998; 65:1187–1191. [PubMed: 9603166]
5. Mazuecos A, Fernandez A, Andres A, et al. HIV infection and renal transplantation. *Nephrol Dial Transplant*. 2011; 26:1401–1407. [PubMed: 20858765]
6. Norman SP, Kommareddi M, Kaul DR. Update on kidney transplantation in HIV-infected recipients. *AIDS Rev*. 2012; 14:195–207. [PubMed: 22833063]

7. Touzot M, Pillebout E, Matignon M, et al. Renal transplantation in HIV-infected patients: the Paris experience. *Am J Transplant*. 2010; 10:2263–2269. [PubMed: 20840478]
8. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. *N Engl J Med*. 2010; 363:2004–2014. [PubMed: 21083386]
9. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN / SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.
10. Stutterheim SE, Bos AE, Pryor JB. Psychological and social correlates of HIV status disclosure: the significance of stigma visibility. *AIDS Educ Prev*. 2011; 23:382–392. [PubMed: 21861610]
11. Kalichman SC, DiMarco M, Austin J, Luke W, DiFonzo K. Stress, social support, and HIV-status disclosure to family and friends among HIV-positive men and women. *J Behav Med*. 2003; 26:315–332. [PubMed: 12921006]
12. Bright PD, Nutt J. The ethics surrounding HIV, kidney donation and patient confidentiality. *J Med Ethics*. 2009; 35:270–271. [PubMed: 19332587]
13. Formica RN Jr, Asch WS, Wagner KR, Kulkarni S. Kidney transplantation and HIV: does recipient privacy outweigh the donor's right to information? *Clin J Am Soc Nephrol*. 2010; 5:924–928. [PubMed: 20203162]
14. Rodrigue JR, Ladin K, Pavlakis M, Mandelbrot DA. Disclosing recipient information to potential living donors: preferences of donors and recipients, before and after surgery. *Am J Transplant*. 2011; 11:1270–1278. [PubMed: 21645257]
15. Rodrigue JR, Pavlakis M, Egbuna O, Paek M, Waterman AD, Mandelbrot DA. The "House Calls" trial: a randomized controlled trial to reduce racial disparities in live donor kidney transplantation: rationale and design. *Contemp Clin Trials*. 2012; 33:811–818. [PubMed: 22510472]
16. Rodrigue JR, Cornell DL, Kaplan B, Howard RJ. A randomized trial of a home-based educational approach to increase live donor kidney transplantation: effects in blacks and whites. *Am J Kidney Dis*. 2008; 51:663–670. [PubMed: 18371542]
17. Rodrigue JR, Cornell DL, Lin JK, Kaplan B, Howard RJ. Increasing live donor kidney transplantation: a randomized controlled trial of a home-based educational intervention. *Am J Transplant*. 2007; 7:394–401. [PubMed: 17173659]
18. Rodrigue JR, Cornell DL, Kaplan B, Howard RJ. Patients' willingness to talk to others about living kidney donation. *Prog Transplant*. 2008; 18:25–31. [PubMed: 18429579]

Figure 1.
Stage of readiness to pursue live donor kidney transplantation (LDKT) by HIV status.

Table 1

LDKT willingness, knowledge, and concerns by HIV status

	HIV-infected (n = 33)	Non-infected (n = 33)	Sig.
LDKT Willingness ¹	2.7 ± 1.9	3.8 ± 1.8	$t = 2.36, P = 0.02$
LDKT Knowledge ²	7.2 ± 1.7	9.1 ± 2.3	$t = 3.89, P < 0.001$
LDKT Concerns ³	44.9 ± 11.0	38.2 ± 8.0	$t = 2.79, P = 0.01$

¹Willingness to talk to others about LDKT: 1 = not at all willingness, 10 = extremely willing

²LDKT Knowledge Questionnaire, 16 True-False items, possible scores 0 to 16, higher scores reflect more knowledge

³LDKT Concerns Questionnaire, 21 Likert-type items (1=not at all, 2=slightly, 3=somewhat, 4=quite a bit, 5=extremely), possible scores range from 21 to 105, higher scores reflect more concerns

Table 2

HIV-specific issues related to pursuit of live donor kidney transplantation (LDKT)

	HIV-infected patients only (n = 33)
Informed someone about HIV status	16 (48%)
Consider HIV status to be barrier in talking about living donation with potential living donors	27 (82%)
Having HIV reduces or lessens chance of receiving LDKT	26 (79%)
Feel uncomfortable sharing HIV status with potential living donors	24 (73%)
Would share HIV status with potential living donors if it might facilitate LDKT	12 (36%)
Willingness to share HIV status with potential living donors	
Very willing	4 (12%)
Willing	8 (24%)
Unwilling	11 (33%)
Very unwilling	10 (30%)

Table 3

Description of study questionnaires

Variable	Description
LDKT willingness	One question asking patients to rate their willingness to talk to family members and/or friends about living kidney donation (1 = “not at all willing” to 7 = “extremely willing”).
LDKT readiness	One question asking patients to identify their stage of readiness to pursue LDKT: Pre-contemplation (“ <i>I am not thinking about or considering LDKT.</i> ”), Contemplation (“ <i>I am now beginning to think about or consider LDKT.</i> ”), Preparation (“ <i>I have thought about LDKT and I am seriously considering this possibility.</i> ”), Action (“ <i>I have thought about LDKT, and I have talked to someone who is willing to be evaluated as a possible living donor.</i> ”), or Maintenance (“ <i>I have thought about LDKT and I have someone who has contacted the transplant center to be evaluated as a potential live donor.</i> ”).
LDKT knowledge	16 true-false questions assessing what patients know about LDKT and living kidney donation (e.g., “ <i>Only a blood relative is able to be a living kidney donor.</i> ” “ <i>A living kidney donor must have his/her own health insurance to cover the costs of surgery.</i> ”). Scores range from 0 to 16, with higher scores reflective of more LDKT knowledge.
LDKT concerns	21 questions measuring patients’ concerns about pursuing LDKT (e.g., “ <i>I am concerned that the donor would no longer be able to do activities that they enjoy.</i> ” “ <i>I am worried that I might do something to ‘waste’ the kidney that someone donates to me – for example, by not living healthy or not taking my medications.</i> ”). Responses to each question are given on a Likert-type scale (1 = not at all concerned to 5 = extremely concerned), with higher scores indicating more concern.
LDKT sources of information	Patients identified (yes, no) primary sources of information about LDKT (e.g., doctor or nurse, brochure, website, etc.).
HIV-specific concerns about LDKT	HIV+ patients only responded to 6 questions assessing the degree to which their HIV status impacts their decisions and behaviors related to LDKT.
Health-related quality of life	SF-36 – a widely used generic health status measure with eight QOL domains: physical functioning, role functioning-physical, role functioning-emotional, vitality, pain, general health, social functioning, and mental health. Higher scores reflect better functioning.